About the Company
We do not have any company description for Glucotrack, Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
8
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Glucotrack, Inc.
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device ...
GlucoTrack Reports Q2 Results and Corporate Highlights
GlucoTrack ( (GCTK) ) has provided an update. On August 14, 2025, Glucotrack, Inc. reported its second quarter financial results and recent corporate highlights. The company is advancing its fully ...
Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering
--Glucotrack, Inc., a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the launch of a" best efforts ...
Glucotrack Announces Repurchase of Series A Warrants
Warrant buyback extinguishes warrant liability accounting and share dilution overhangRUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company ...
Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday?
Glucotrack’s device showed a 7.7% MARD, 99% data capture, and zero serious adverse events in a human trial. The device measured glucose from blood, not fluid, and had 92% values in the green ...
Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology
(GLOBE NEWSWIRE) -- (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that David S.
Expanding Continuous Glucose Monitoring Options: How Glucotrack Is ...
Long DXCM DexCom Inc $81.99 -1.04 % GCTK GlucoTrack Inc $0.0929 -12.3 % MDT Medtronic PLC $87.27 -1.38 % ...
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE ...
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified ...
GlucoTrack, Inc.: Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Ex ...
Glucotrack, Inc. Announces Pricing of $10.0 Million Public Offering
Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for ...
Similar Companies
Loading the latest forecasts...